NASS 2019 Annual Meeting

Vivex Biologics, Inc. 

Booth 2027

Miami, FL  
      United States

Learn more about our new products and clinical evidence at NASS booth 2027; VIA Disc Matrix and VIA Cellular Matrices.  Vivex Biologics, Inc. strives to create treatment options and solutions that will improve clinical, surgical and therapeutic patient care through innovation.  Vivex works with services that are committed to providing care and compassion to donor families while inspiring communities to share life through their donation.  Partnering with families in the prospect of regenerative options, Vivex assures appropriate options are available to support regeneration and translation of their gifts.





In 2014, Vivex Biologics Inc. acquired UMTB, building on UMTB’s strong history, quality, and technology while advancing UMTB to become an industry leader in regenerative medicine. Today, Vivex focuses on core products and new technologies to meet the ever-growing biologic needs of surgeons and patients while continuing our 45-year history of serving and honoring both tissue donors and recipients. Together, Vivex and UMTB have distributed more than 2 million tissue allografts to 18 countries worldwide to better serve the needs of patients.



Product Categories

Biomaterials
- Bone Graft Matrix
- Bone Substitute Material
- Stem Cells Biologics

Fusion
- Spine Fusion

Implants
- Allografts

Pain Management / Rehabilitation
- Intradiscal injection

Spine Biologics
- Allografts
- Bone Substitutes and Machined Bones
- Demineralized Bone Matrix